Skip to main content

Table 1 (abstract P196). See text for description

From: Proceedings of the 25th European Paediatric Rheumatology Congress (PReS 2018)

Patient Group

JIA (N=119)

ALL (N=22)

p

Age, median (IQR) years

13.3 (11.3-15.1)

11.9 (10.2-14.6)

0.18

Gender, girls: boys

81 : 38

9 : 13

-

MTXO: MTXSC, n

45 : 74

22 : 0

-

MTX dose, median (IQR) mg/m2/week

9.7 (9.0-10.9)

14.7 (10.4-20.0)

0.0002

 MTXintol : MTXtol

9.6 (8.6-11.0) : 10.1 (9.4-10.9)a

16.3 (14.7-18.4): 13.3 (9.0-21.0)b

a0.22 ; b0.55

E-MTX-PG, mean (95% CI) nmol/ mmol Hb

5.3 (4.9-5.6)

6.5 (5.5-7.6)

0.028

 MTXintol: MTXtol

5.4 (5.0-5.9) : 5.0 (4.5-5.5)a

7.6 (4.5-10.8) : 6.3 (5.0-7.5)b

a0.21; b0.31

MTX treatment duration, median (IQR) days

336 (141-766)

114 (71-254)

0.0003

 MTXintol: MTXtol

370 (143-766) : 262 (141-629)a

300 (191-354) : 97 (64-197)b

a0.38 ; b0.033